Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 3/20 | 0.56 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
| ▸ | LIPC | P11150 | 1/20 | 0.41 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.41 |
| ▸ | VCP | P55072 | 1/20 | 0.40 |
| ▸ | RORC | P51449 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL584389 | 0.94 | PTGER4 (0.51) | PTGER4PIK3C3TDP1MAPK14ALDH1A1 | |
| SCHEMBL3970983 | 0.93 | PTGER4 (0.50) | PTGER4PIK3C3TDP1MAPK14ALDH1A1 | |
| SCHEMBL1609124 | 0.91 | PTGER4 (0.48) | PTGER4PIK3C3TDP1MAPK14ALDH1A1 | |
| SCHEMBL584850 | 0.89 | PTGER4 (0.46) | PTGER4PIK3C3TDP1MAPK14ALDH1A1 | |
| SCHEMBL5881896 | 0.86 | PTGER4 (0.57) | PTGER4PIK3C3TDP1ALDH1A1LIPC | |
| SCHEMBL24320321 | 0.84 | TDP1 (0.44) | PTGER4TDP1ALDH1A1HDAC1HDAC3 | |
| SCHEMBL26914476 | 0.84 | TDP1 (0.44) | PTGER4TDP1ALDH1A1HDAC1HDAC3 | |
| SCHEMBL3930758 | 0.81 | PTGER4 (0.51) | PTGER4ALDH1A1LIPCLIPGKDM4E | |
| SCHEMBL3070660 | 0.81 | HTT (0.58) | TDP1ALDH1A1HDAC1HDAC3HDAC2 | |
| SCHEMBL13876936 | 0.81 | PTGER4 (0.51) | PTGER4ALDH1A1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200061063-A1 | BICYCLICALLY SUBSTITUTED URACILS AND THE USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-02-27 | — | — | US | disclosed |
| US-20200061063-A1 | BICYCLICALLY SUBSTITUTED URACILS AND THE USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-02-27 | — | — | US | disclosed |
| CN-106983751-B | Bicyclic substituted uracils and their use | 拜耳医药股份有限公司 | 2020-01-07 | — | — | CN | disclosed |
| US-10300062-B2 | Bicyclically substituted uracils and the use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-05-28 | — | — | US | disclosed |
| US-10300062-B2 | Bicyclically substituted uracils and the use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-05-28 | — | — | US | disclosed |
| US-20180256576-A1 | BICYCLICALLY SUBSTITUTED URACILS AND THE USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-09-13 | — | — | US | disclosed |
| US-9949978-B2 | Bicyclically substituted uracils and the use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-04-24 | — | — | US | disclosed |
| US-9949978-B2 | Bicyclically substituted uracils and the use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-04-24 | — | — | US | disclosed |
| US-9949977-B2 | Bicyclically substituted uracils and the use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-04-24 | — | — | US | disclosed |
| US-9949977-B2 | Bicyclically substituted uracils and the use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-04-24 | — | — | US | disclosed |
| US-20150148340-A1 | BICYCLICALLY SUBSTITUTED URACILS AND THE USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-05-28 | — | — | US | disclosed |
| EP-2847190-A1 | BICYCLICALLY SUBSTITUTED URACILS AND THE USE THEREOF | Bayer Pharma Aktiengesellschaft (DE) | 2015-03-18 | — | — | EP | disclosed |
| WO-2013167495-A1 | BICYCLICALLY SUBSTITUTED URACILS AND THE USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2013-11-14 | — | — | WO | disclosed |
| US-20060135554-A1 | Novel compounds | ASTRAZENECA AB (SE) | 2006-06-22 | — | — | US | disclosed |
| US-7030139-B2 | Compounds | ASTRAZENECA AB (SE) | 2006-04-18 | — | — | US | disclosed |
| CN-1250531-C | Novel compounds | ASTRAZENECA AB (SE) | 2006-04-12 | — | — | CN | disclosed |
| US-20040116465-A1 | Novel compounds | ASTRAZENECA AB (SE) | 2004-06-17 | — | — | US | disclosed |
| CN-1503787-A | Novel compounds | — | 2004-06-09 | — | — | CN | disclosed |
| EP-1390350-A1 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2004-02-25 | — | — | EP | disclosed |
| WO-2002085866-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2002-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135554-A1 | Novel compounds | OPRL1, OPRK1, TRPV1 | PTGER4 188/4885PIK3C3 4428/4885TDP1 3487/4885 |
| US-10300062-B2 | Bicyclically substituted uracils and the use thereof | UNG, UMPS, TYMP | PTGER4 3754/4885PIK3C3 1004/4885TDP1 151/4885 |
| US-20200061063-A1 | BICYCLICALLY SUBSTITUTED URACILS AND THE USE THEREOF | UNG, UMPS, TYMP | PTGER4 3754/4885PIK3C3 1004/4885TDP1 151/4885 |
| US-20150148340-A1 | BICYCLICALLY SUBSTITUTED URACILS AND THE USE THEREOF | UNG, UMPS, TYMP | PTGER4 3754/4885PIK3C3 1004/4885TDP1 151/4885 |
| US-20180256576-A1 | BICYCLICALLY SUBSTITUTED URACILS AND THE USE THEREOF | UNG, UMPS, TYMP | PTGER4 3754/4885PIK3C3 1004/4885TDP1 151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.